购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

BMS-599626

产品编号 T2610Cas号 714971-09-2
别名 AC480

BMS-599626 (AC480) 是可口服的选择性 HER1和HER2抑制剂,IC50分别为 20 和 30 nM。它对 HER4 的 IC50值为 190 nM,可抑制肿瘤细胞增殖,有治疗肿瘤的潜力。

BMS-599626

BMS-599626

纯度: 无数据
产品编号 T2610 别名 AC480Cas号 714971-09-2

BMS-599626 (AC480) 是可口服的选择性 HER1和HER2抑制剂,IC50分别为 20 和 30 nM。它对 HER4 的 IC50值为 190 nM,可抑制肿瘤细胞增殖,有治疗肿瘤的潜力。

规格价格库存数量
10 mg¥ 3,90035日内发货
25 mg¥ 8,92035日内发货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"BMS-599626"的相关化合物库

选择批次:
联系我们获取更多批次信息
资源下载
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
BMS-599626 (AC480) has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.
靶点活性
HER2:30 nM, HER4:190 nM, HER1:20 nM
体外活性
在体内,口服60 mg/kg到240 mg/kg范围的BMS-599626,导致剂量依赖性抑制 Sal2肿瘤生长,在其人乳腺肿瘤KPL-4异种移植物中产生有效的抗肿瘤活性最大耐受剂量为180 mg/kg,并且在其他HER2扩增异种移植模型以及其他HER1过表达异种移植模型中也具有类似的抗肿瘤活性.
体内活性
MS-599626抑制表达高水平HER1和/或HER2的肿瘤细胞增殖,包括Sal2,BT474,N87,KPL-4,HCC202,HCC1954,HCC1419,AU565,ZR-75-30,MDA-MB-175,GEO和PC9细胞,IC50分别为0.24 μM,0.31 μM,0.45 μM,0.38 μM,0.94 μM,0.34 μM,0.75 μM,0.63 μM,0.51 μM,0.84 μM,0.90 μM和0.34 μM。BMS-599626选择性抑制重组HER1和HER2激酶的酶活性,IC50分别为20 nM和30 nM。BMS-599626通过促进周期重新分布和抑制DNA修复,显著增强了表达EGFR和Her2细胞的HN-5细胞的放射敏感性。此外,BMS-599626也抑制相关受体HER4,但是效力较低,IC50为190 nM。BBMS-599626不会明显抑制不表达HER1或HER2的卵巢肿瘤细胞系A2780和MRC5成纤维细胞的增殖。
激酶实验
Protein kinase assays: The entire cytoplasmic sequences of HER1, HER2, and HER4 are expressed as recombinant proteins in Sf9 insect cells. HER1 and HER4 are expressed as fusion proteins with glutathione-S-transferase and are purified by affinity chromatography on glutathione-S-Sepharose. HER2 is subcloned into the pBlueBac4 vector and expressed as an untagged protein using an internal methionine codon (M687) for translation initiation. The truncated HER2 protein is isolated by chromatography on a column of DEAE-Sepharose equilibrated in a buffer that contains 0.1 M NaCl, and the recombinant protein is eluted with a buffer containing 0.3 M NaCl. For the HER kinase assays, reaction volumes are 50 μL and contains 10 ng of glutathione-S-transferase fusion protein or 150 ng of partially purified HER2. The mixtures also contains 1.5 μM poly(Glu/Tyr) (4:1), 1 μM ATP, 0.15 μCi [γ-33P]ATP, 50 mM Tris-HCl (pH 7.7), 2 mM DTT, 0.1 mg/mL bovine serum albumin, and 10 mM MnCl2. Reactions are allowed to proceed at 27°C for 1 hour and are terminated by the addition of 10 μL of a stop buffer (2.5 mg/mL bovine serum albumin and 0.3 M EDTA), followed by a 108-μL mixture of 3.5 mM ATP and 5% trichloroacetic acid. Acid-insoluble proteins are recovered on GF/C Unifilter plates with a Filtermate harvester. Incorporation of radioactive phosphate into the poly(Glu/Tyr) substrate is determined by liquid scintillation counting. Percent inhibition of kinase activity is determined by nonlinear regression analyses and data are reported as the inhibitory concentration required to achieve 50% inhibition relative to control reactions (IC50). Data are the averages of triplicate determinations. All other tyrosine kinases are also assayed using poly(Glu/Tyr) as a substrate. Kinetics of HER1 and HER2 inhibition are determined in reaction mixtures that contains varying concentrations of ATP and BMS-599626.
细胞实验
All cell lines are maintained in RPMI 1640 supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 μg/mL streptomycin. Cells are plated at 1,000 per well in 96-well plates and are cultured for 24 hours before BMS-599626 is added. BMS-599626 is diluted in culture medium such that the final concentrations of DMSO are ≤ 1%. Following the addition of BMS-599626, the cells are cultured for an additional 72 hours before cell viability is determined by measuring the conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye with the CellTiter96 kit. For some cell lines, there is a lack of a correlation between 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye metabolism and cell number, and a thymidine uptake assay is used to measure proliferation of these cell lines. Cells are plated in 96-well plates and treated with compounds as above. At the end of the 72-hour incubation, cells are pulsed with [3H]thymidine (0.4 μCi/well) for 3 hours before they are harvested. Cells are digested with 2.5% trypsin for 10 minutes at 37 °C and are harvested by filtration using a Packard Filtermate Harvester and GF/C Unifilter plates. Incorporation of radioactive thymidine into nucleic acids is determined by liquid scintillation counting.(Only for Reference)
别名AC480
化学信息
分子量530.55
分子式C27H27FN8O3
CAS No.714971-09-2
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
H2O: <1 mg/mL
DMSO: 104 mg/mL (196 mM)
Ethanol: 16 mg/mL (30.2 mM)
溶液配制表
Ethanol/DMSO
1mg5mg10mg50mg
1 mM1.8848 mL9.4242 mL18.8484 mL94.2418 mL
5 mM0.3770 mL1.8848 mL3.7697 mL18.8484 mL
10 mM0.1885 mL0.9424 mL1.8848 mL9.4242 mL
20 mM0.0942 mL0.4712 mL0.9424 mL4.7121 mL
DMSO
1mg5mg10mg50mg
50 mM0.0377 mL0.1885 mL0.3770 mL1.8848 mL
100 mM0.0188 mL0.0942 mL0.1885 mL0.9424 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

Related Tags: buy BMS-599626 | purchase BMS-599626 | BMS-599626 cost | order BMS-599626 | BMS-599626 chemical structure | BMS-599626 in vivo | BMS-599626 in vitro | BMS-599626 formula | BMS-599626 molecular weight